PLAINSBORO, N.J., April 11, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, announced today that it will feature its latest innovations at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, April 13–17, 2019 in San Diego, California.
“Neurosurgery is a dynamic and challenging area where improvement to our tools is a critical enabler to optimizing patient care,” said Dr. Uzma Samadani, a neurosurgeon and Ph.D. researcher in Minneapolis, Minnesota. “Integra’s CereLink™ Intracranial Pressure Monitor introduces new ways to capture and share important information I need to manage patients with serious, life-threatening conditions, such as traumatic brain injuries.”
Integra’s Codman Specialty Surgical division will exhibit its new innovations at AANS (Booth #917), including:
- CereLink™ Intracranial Pressure (ICP) Monitoring System: This advanced technology provides neurocritical care teams with more accuracy in terms of less drift over time, more protection due to MR conditional capability, more choice due to durable, flexible ICP sensors, and more information due to its advanced data presentation than current ICP monitoring technologies.1,[2],[3]
- CUSA® Clarity Tough Tissue Technology: Integra’s latest handpiece with new surgical tips enables surgeons to remove fibrous tissue and bone swiftly and safely. These are important additions to Integra’s CUSA Clarity Ultrasonic Tissue Ablation platform, which has been adopted by 30 percent of the top neurosurgery and neuro pediatric hospital programs in the U.S.4
- Certas™ Plus Portfolio Expansion: Continuing to build on a strong legacy in cerebral spinal fluid management, Integra’s Certas Plus Programmable Valve portfolio provides surgeons a wide range of options for managing hydrocephalus patients. Also, the new Certas Plus Electronic Tool Kit limits uncertainty for surgeons, enabling them to efficiently change and confirm the settings of these programmable valves.5
- Integra® Duo LED Surgical Headlight: Integra’s new innovation in surgical headlights offers surgeons superior comfort and brighter visualization compared to current surgical headlight technology.6
“We’re excited to share a range of new solutions to address surgeons’ specialty and neurosurgical needs at this year’s AANS annual meeting,” said Dan Reuvers, corporate vice president and president, Codman Specialty Surgical, Integra LifeSciences. “The successful integration of the U.S. Codman business has yielded a host of new products that enrich our extensive portfolio and reinforce Integra’s commitment to supporting the surgeon and patient throughout the continuum of care.”
Integra continues to support surgeons with hands-on clinical courses at the AANS including: Update on Techniques and Equipment for Neurosurgical Patient Positioning, Deep Brain Stimulation - Update and New Directions and Case-based Management of Traumatic Brain Injury.
About Integra
Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas™, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™. For the latest news and information about Integra and its brands, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2018 and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.
Investor Relations Contacts:
Sravan Emany
Senior Vice President, Strategy, Treasury & Investor Relations
(609) 936-2488
sravan.emany@integralife.com
Michael Beaulieu
Director, Investor Relations
(609) 750-2827
michael.beaulieu@integralife.com
Media Contact:
Laurene Isip
Senior Director, Global Corporate Communications
(609) 750-7984
laurene.isip@integralife.com
1 Camino system IFUs and CereLink IFUs.
2 Crutchfield JS, Narayan RK, Robertson CS, Michael LH. Evaluation of a fiberoptic intracranial pressure monitor. J Neurosurg. 1990;72(3):482-487.
3 Camino® IFU data states max draft ±6 mmHg over 5 days; CereLink bench test shows max (2stdev) of ±2.2mmHg over 7 days.
4 Based on U.S. News and World Report rankings of Best Neuro and Neuro Pediatric Hospitals.
5 Design validation and summative usability evaluation of the CERTAS Plus System. Integra Lifesciences, Plainsboro, NJ, USA.
6 All comparisons based on bench testing vs. Sunoptic Surgical® SSL-9500. Data on file. Integra LifeSciences, Plainsboro, NJ USA.
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/22f55c2b-42b4-41f9-bb7c-00774d530806
http://www.globenewswire.com/NewsRoom/AttachmentNg/0b28b4d4-bfdc-4684-aaa3-857cc93da0d1